Viewpoint Therapeutics, Inc.
SAN FRANCISCO, CA · Founded 2014 · CIK 0001673242 · Biotech · Acquired
Pharmacological chaperone small molecules that stabilize misfolded myocilin protein to treat myocilin-linked open-angle glaucoma
- Grants
- $447K
- 2 awards
- Sector median: 1
- Raised
- $25M
- 2 Form D · Mar 2018
- 103 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 10
- 0 granted · 10 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of a Topical Treatment for Cataract | $221,978 | |
| Private capital raised | Form D · SEC | $3,981,337 | |
| Private capital raised | Form D · SEC | $20,935,629 | |
| Federal grant | Department of Health and Human Services · Phase I · Pharmacological chaperones for the treatment of Open-Angle Glaucoma | $225,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1494 | MITOSENSE, INC. | — | $2.2M |
| 1495 | GFREE BIO, LLC | — | — |
| 1496 | BEXION PHARMACEUTICALS, INC. | — | — |
| 1497 | Viewpoint Therapeutics, Inc. | — | $25M |
| 1498 | Enzyme by Design Inc. | — | — |
| 1499 | Calporta Therapeutics | — | — |
| 1500 | Atavistik Bio | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Mark Blumenkranz, M.D.Director
- Douglas CrawfordDirector
- Emmett Cunningham, Jr.Director
- Jason GestwickiDirector
- Ed HurwitzDirector · Executive Officer
- Heath LukatchDirector
- Leah MakleyDirector · Executive Officer
- Peter MoldtDirector
Patents
- Compounds For Treating Near Vision Disordersapplication
- Compounds And Formulations For Treating Ophthalmic Diseasesapplication
- Compounds For Treating Near Vision Disordersapplication
- Compounds For Treating Near Vision Disordersapplication
- Compounds And Formulations For Treating Ophthalmic Diseasesapplication
- Nanoparticle Formulations Of 25-Hydroxycholesterolapplication
- Microemulsion formulations of 25-hydroxycholesterolapplication
- Compounds And Formulations For Treating Ophthalmic Diseasesapplication
- Pharmacological Chaperones For Inhibition Of Amyloid Formation And Formulations Thereofapplication
- Compounds And Formulations For Treating Ophthalmic Diseasesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.